scholarly article | Q13442814 |
P356 | DOI | 10.1080/10543400902800478 |
P698 | PubMed publication ID | 19384686 |
P2093 | author name string | Cong Chen | |
Robert A Beckman | |||
P2860 | cites work | A flexible design for multiple armed screening trials | Q33181833 |
Design issues of randomized phase II trials and a proposal for phase II screening trials | Q40385205 | ||
Decision-theoretic designs for pre-phase II screening trials in oncology | Q40669546 | ||
The sample size for a clinical trial: a Bayesian-decision theoretic approach | Q43544194 | ||
Sample size calculation for a proof of concept study | Q44202724 | ||
New designs for phase 2 clinical trials | Q44298388 | ||
Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
P433 | issue | 3 | |
P921 | main subject | phase II clinical trial | Q42824440 |
P304 | page(s) | 424-436 | |
P577 | publication date | 2009-01-01 | |
P1433 | published in | Journal of Biopharmaceutical Statistics | Q15764587 |
P1476 | title | Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. | |
P478 | volume | 19 |
Q39489357 | A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk |
Q44644308 | A portfolio-based approach to optimize proof-of-concept clinical trials |
Q33433456 | Current issues in oncology drug development, with a focus on Phase II trials |
Q38660962 | Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution. |
Q36925422 | Decision-theoretic designs for small trials and pilot studies: A review |
Q38209093 | Emerging drugs for neuropathic pain |
Q47912286 | Evaluation of early efficacy endpoints for proof-of-concept trials |
Q41489822 | Evaluation of program success for programs with multiple trials in binary outcomes |
Q37940788 | Integrating predictive biomarkers and classifiers into oncology clinical development programmes |
Q37353962 | New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs |
Q37481946 | PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms |
Q38578613 | Translating predictive biomarkers within oncology clinical development programs |
Search more.